A5088925800- Malaria Research and Control
- Mosquito-borne diseases and control
- Computational Drug Discovery Methods
- Trypanosoma species research and implications
- Hepatitis C virus research
- Research on Leishmaniasis Studies
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- SARS-CoV-2 and COVID-19 Research
- Travel-related health issues
- Drug-Induced Hepatotoxicity and Protection
- Hepatitis Viruses Studies and Epidemiology
- Hemoglobinopathies and Related Disorders
- Traditional and Medicinal Uses of Annonaceae
- Infectious Encephalopathies and Encephalitis
- COVID-19 Clinical Research Studies
- Neonatal Health and Biochemistry
- Parasites and Host Interactions
Université des Sciences, des Techniques et des Technologies de Bamako
2021-2024
University of Bamako
2024
National Institute of Malaria Research
2020
BackgroundRecently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical with seasonal administration in phase 2b trial Burkina Faso. Here, report on safety and of the vaccine 3 enrolling 4800 children across four countries followed for up to 18 months at sites 12 standard sites.MethodsWe did double-blind, randomised, R21/Matrix-M five African differing transmission intensities seasonality. Children (aged 5–36 months) were enrolled randomly assigned (2:1)...
BackgroundArtemether–lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine–pyrimethamine plus amodiaquine seasonal malaria chemoprevention. We aimed to determine the efficacy of artemether–lumefantrine with and without primaquine tafenoquine reducing gametocyte carriage transmission mosquitoes.MethodsIn this phase 2, single-blind, randomised clinical trial conducted in Ouelessebougou, Mali, asymptomatic individuals aged 10–50 years P gametocytaemia were...
Pyronaridine-artesunate is the most recently licensed artemisinin-based combination therapy. WHO has recommended that a single low dose of primaquine could be added to therapies reduce
BackgroundTafenoquine was recently approved as a prophylaxis and radical cure for Plasmodium vivax infection, but its falciparum transmission-blocking efficacy is unclear. We aimed to establish the safety of three single low doses tafenoquine in combination with dihydroartemisinin–piperaquine reducing gametocyte density transmission mosquitoes.MethodsIn this four-arm, single-blind, phase 2, randomised controlled trial, participants were recruited at Clinical Research Unit Malaria Training...
Summary Background Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine seasonal malaria chemoprevention. We determined the efficacy of artemether-lumefantrine with and without primaquine tafenoquine reducing gametocyte carriage transmission to mosquitoes. Methods In this phase 2, single-blind, randomised clinical trial conducted, asymptomatic individuals aged 10-50 years P. gametocytaemia were (1:1:1:1) receive...
Background: Plasmodium falciparum (Pf) parasitemia during pregnancy causes maternal, fetal, and infant mortality. We conducted two trials in Ouélessébougou, Mali to optimize PfSPZ Vaccine dosage, schedule, antimalarial pre-treatment for future maternal immunizations.Methods: In MLSPZV3 trial (NCT03510481), we randomly assigned healthy 18-35-year-olds 3 doses of 9x105 (versus placebo) at 0,1,4-weeks or 0,8,16-weeks without pre-treatment, with 1-year booster dose. MLSPZV4 (NCT03989102),...
Summary Background Triple artemisinin-based combination therapies, such as artemether-lumefantrine-amodiaquine, can delay the spread of antimalarial drug resistance; artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We aimed to determine efficacy artemether-lumefantrine-amodiaquine and with without single low-dose primaquine reducing gametocyte carriage transmission mosquitoes. Methods conducted a five-arm, single-blind, phase 2, randomised clinical trial...
ABSTRACT Background Interrupting human-to-mosquito transmission is important for malaria elimination strategies as it can reduce infection burden in communities and slow the spread of drug resistance. Antimalarial medications differ their efficacy clearing stages Plasmodium falciparum (gametocytes) preventing mosquito infection. Here we present a combined analysis six trials conducted at same study site with highly consistent methodologies that allows direct comparison gametocytocidal...
Abstract Background More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended 2012 by WHO. This strategy is now implemented widely protected more 19 children 2018. It previously reported that exposure to SMC reduced antibody levels AMA1, MSP-1 42 CSP, but the duration up three 3 years, had no effect on CSP. Methods In 2017, a cross-sectional survey...
In some settings, sensitive field diagnostic tools may be needed to achieve elimination of falciparum malaria. To this end, rapid tests (RDTs) based on the detection Plasmodium protein HRP-2 are being developed with increasingly lower limits detection. However, it is currently unclear how parasite stages that unaffected by standard drug treatments contribute detectability and potentially confound RDT results even after clearance blood stage infection. This study assessed in periods...
Abstract Background Malaria control in sub-Saharan Africa relies upon prompt case management with artemisinin-based combination therapy (ACT). Ring-stage parasite mRNA, measured by sbp1 quantitative reverse-transcriptase PCR (qRT-PCR), was previously reported to persist after ACT treatment and hypothesized reflect temporary arrest of the growth ring-stage parasites (dormancy) following exposure artemisinins. Here, persistence parasitaemia non-ACT examined. Methods Samples were used from...
Malaria has been hypothesized as a factor that may have reduced the severity of COVID-19 pandemic in sub-Saharan Africa. To evaluate effect recent malaria on we assessed subgroup individuals participating longitudinal cohort serosurvey were also undergoing intensive monitoring part antimalarial vaccine trials during 2020 transmission season Mali. These communities experienced high incidence primarily asymptomatic or mild and 2021. In 1314 individuals, 711 parasitemic season; 442 symptomatic...
Triple artemisinin-based combination therapies (TACTs) can delay the spread of antimalarial drug resistance. Artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We therefore aimed to determine safety and efficacy artemether-lumefantrine-amodiaquine artesunate-amodiaquine with without single low-dose primaquine reducing gametocyte carriage transmission mosquitoes. did a five-arm, single-blind, phase 2 randomised controlled trial at Ouélessébougou Clinical...
Abstract Sequence analysis of Plasmodium falciparum parasites is informative in ensuring sustained success malaria control programmes. Whole-genome sequencing technologies provide insights into the epidemiology and genome-wide variation P. populations can characterise geographical as well temporal changes. This particularly important to monitor emergence spread drug resistant which threatening programmes world-wide. Here, we a detailed characterisation genetic resistance profiles...
Background: Tafenoquine (TQ) was recently approved as prophylaxis and radical cure for P. vivax infection, but its falciparum transmission-blocking efficacy is unclear. We determined safety of single doses TQ in combination with dihydroartemisinin-piperaquine (DP) reducing gametocyte density transmission to mosquitoes.Methods: In this single-blind, phase 2 randomised clinical trial, participants (12-50 years age) asymptomatic microscopy-detected carriage (n=80) were randomized standard...
Abstract Background Malaria control in sub-Saharan Africa relies upon prompt case management with artemisinin-based combination therapy (ACT). Ring-stage parasites, measured by sbp1 quantitative reverse-transcriptase PCR (qRT-PCR), were previously reported to persist after ACT treatment and hypothesized reflect temporary arrest of the growth ring-stage parasites (dormancy) following exposure artemisinins. Here, persistence parasitemia non-ACT was examined. Methods Samples used from naturally...
Abstract Background: Malaria control in sub-Saharan Africa relies upon prompt case management with artemisinin-based combination therapy (ACT). Ring-stage parasites, measured by sbp1 quantitative reverse-transcriptase PCR (qRT-PCR), were previously reported to persist after ACT treatment and hypothesized reflect temporary arrest of the growth ring-stage parasites (dormancy) following exposure artemisinins. Here, we examined persistence parasitemia non-ACT treatment. Methods: We used samples...
Abstract Background In some settings, sensitive field diagnostic tools may be needed to achieve elimination of falciparum malaria. To this end, rapid tests (RDTs) based on the detection Plasmodium protein HRP-2 are being developed with increasingly lower limits detection. However, it is currently unclear how parasite stages that unaffected by standard drug treatments contribute detectability and potentially confound RDT results even after clearance blood stage infection. study, we assessed...
Summary: Pyronaridine-artesunate (PA) is a recommended anti-malarial in areas of Plasmodium resistance to first-line artemisinin combination therapies. This study shows that PA may be combined with single low dose primaquine for highly effective P. falciparum transmission reduction.Background: the most recently licenced therapies (ACT). The World Health Organization recommends lose added ACTs reduce aiming elimination or threatened by resistance. reducing efficacy and have never been...